Integra LifeSciences Holdings Corporation — 2011 Form 10-K Summary
Business context and reporting period
Integra is a global medical-device company serving orthopedic extremity and spine surgery, neurosurgery, reconstructive and general surgery, and surgical instruments. It reported one operating segment. The filing covers the fiscal year ended December 31, 2011; fourth-quarter information is included on an unaudited basis.
- Approximately 3,400 employees; approximately 76% of revenue was generated in the United States.
- Core strategy: geographic expansion, manufacturing and margin improvement, platform synergies, quality-system enhancement, and acquisitions.
- 2011 acquisitions included SeaSpine for approximately $89.0 million and Ascension Orthopedics for approximately $66.5 million.
Financial performance and key metrics
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Revenue | $780.1 million | $732.1 million | Up 7.0% |
| Gross profit | $480.9 million | $463.9 million | Up 3.7% |
| Gross margin | 61.7% | 63.4% | Down 170 basis points |
| Operating income | $54.9 million | $98.7 million | Down 44.4% |
| Net income | $28.0 million | $65.7 million | Down 57.4% |
| Diluted EPS | $0.95 | $2.17 | Down 56.2% |
| Operating cash flow | $104.3 million | $105.6 million | Down 1.2% |
- Revenue by category: Orthopedics $328.8 million, up 13%; Neurosurgery $285.3 million, up 4%; Instruments $166.0 million, down 1%.
- Fourth-quarter revenue was $203.5 million versus $194.1 million in the prior-year quarter. Fourth-quarter net income was $4.6 million versus $18.8 million.
- 2011 operating margin was approximately 7.0%, compared with 13.5% in 2010; net margin was approximately 3.6%, compared with 9.0%.
- Cash and equivalents were $100.8 million at year-end, compared with $128.8 million in 2010. Working capital increased to $350.4 million from $243.0 million.
- Year-end total assets were $1.14 billion and stockholders’ equity was $492.6 million.
- Cash used in investing activities was $190.4 million, including $152.0 million for acquisitions and $38.4 million for capital expenditures.
Debt, liquidity and capital allocation
- Borrowings under the senior credit facility were $179.7 million, with approximately $420.3 million of remaining borrowing capacity. The facility matures June 8, 2016 and was secured by substantially all assets of U.S. subsidiaries, excluding intangible assets.
- Convertible debt included $165.0 million of 2.375% notes due June 2012 and $230.0 million of 1.625% notes due December 2016. Carrying value of convertible securities was $352.6 million.
- Management expected existing cash, operating cash flow, and available credit capacity to meet foreseeable needs for at least the next twelve months.
- 2012 planned cash uses included repayment of the $165 million 2012 Notes, $65 million to $75 million of capital expenditures, regenerative-medicine capacity expansion, and ERP implementation.
- Net cash position, defined as cash less senior-credit-facility borrowings and convertible securities, was negative $431.5 million at year-end versus negative $274.5 million in 2010.
- The company repurchased $83.5 million of common stock during 2011; $29.1 million remained available under the repurchase authorization. No cash dividends have been paid since formation.
Material changes, outlook and unusual items
- Net income was pressured by $65.5 million of identified special charges, compared with $21.1 million in 2010. Major items included $17.1 million of ERP implementation costs, $13.3 million of CEO-related stock compensation, $5.8 million of Plainsboro remediation and underutilization costs, $5.3 million of acquisition costs, and $10.5 million of non-cash convertible-debt interest amortization.
- Gross margin declined because of inventory write-offs and reserves, acquisition-related inventory step-ups, higher manufacturing costs, product discontinuations, and FDA-related production disruption.
- FDA issued a December 2011 warning letter concerning quality-system and compliance issues at the Plainsboro, New Jersey facility. The letter did not restrict manufacturing or shipments and did not require a product recall, but remediation remained ongoing. Management expected approximately $1.5 million of additional remediation expense in 2012.
- Production of certain regenerative-medicine products was below normal because of the remediation program. Management expected normal production in the first quarter of 2012 and resolution of dermal-wound-product shortages in the second quarter.
- Management expected 2012 gross margin to be approximately flat with 2011, with benefits from fewer inventory write-offs offset by acquisition-related inventory amortization, regenerative-medicine expansion costs, and private-label volume pressure.
- Management targeted 2012 research and development spending of approximately 6.5% to 7.0% of revenue, SG&A excluding special charges of approximately 41% of revenue, and an effective tax rate of 16% to 18%.
- Key operating risks include reimbursement reductions, competitive pricing and technology, regulatory approval delays, quality-system compliance, product liability, supply-chain concentration, foreign-exchange exposure, acquisition integration, goodwill and intangible-asset impairment, and healthcare reform including the scheduled 2.3% medical-device excise tax after December 31, 2012.
- Legal matters included a $4.6 million settlement related to the former Theken acquisition and a product-liability settlement of approximately $4.6 million that was covered by insurance and had no net income impact. Management stated that other proceedings were not expected to be materially adverse, although period-specific impacts remain possible.
- Management and the independent auditor concluded that internal control over financial reporting was effective at December 31, 2011; the assessment excluded the recently acquired SeaSpine and Ascension entities.
Most important facts for investors to verify
- Whether Plainsboro remediation was completed, FDA restrictions were lifted, and regenerative-medicine production and product availability returned to normal.
- Actual cash funding and refinancing of the $165 million 2012 Notes and the effect on leverage and interest expense.
- Whether acquisition-related revenue growth converts into sustainable operating-margin improvement after inventory step-ups, integration costs, and amortization.
- Fourth-quarter and 2012 trends in orthopedic spine, extremity reconstruction, private-label instruments, and international revenue.
- Progress and final cost of the global ERP implementation and facility-consolidation programs.
- Exposure to reimbursement changes, the medical-device excise tax, regulatory changes, product liability, and potential goodwill or intangible-asset impairment.
- Future share repurchases, potential dilution from convertible notes and warrants, and the company’s continued absence of a dividend.